A Massachusetts drug developer has created an opiate painkiller that testing shows to be less likely to get users high.
Boston Business Journal BioFlash editor Don Seiffert joins necn to discuss his story, "Trial shows Canton firm's opiate is more resistant to abuse than OxyContin."